Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05978531 · ClinicalTrials.gov registry record
Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice
A clinical trial, sponsored by Banner Life Sciences.
- Terminated
- Registry status
- 25
- Enrollment target
NCT05978531: Clinical Trial study, sponsored by Banner Life Sciences.
NCT05978531 is a clinical trial that was terminated before completion, run by Banner Life Sciences. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05978531 was terminated before completion, sponsored by Banner Life Sciences.
- TERMINATED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, observational study of the adherence of patients with relapsing-remitting multiple sclerosis (RRMS) prescribed Bafiertam (monomethyl fumarate) as their treatment.
Primary Outcome
Percentage of participants on treatment with Bafiertam at 1 Year.
Interventions
- DRUG Monomethyl Fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-08-17 |
| Est. Completion | 2025-02-24 |
Why NCT05978531 stopped before completion
NCT05978531 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Monomethyl Fumarate is the first listed.
NCT05978531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05978531 about?
NCT05978531 is a clinical study titled "Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice". This is an open-label, multicenter, observational study of the adherence of patients with relapsing-remitting multiple sclerosis (RRMS) prescribed Bafiertam (monomethyl fumarate) as their treatment.
What is the current status of trial NCT05978531?
This trial is currently terminated. The enrollment target is 25 participants. The study started on 2023-08-17. Estimated completion is 2025-02-24.
What interventions are being tested in trial NCT05978531?
The interventions under investigation include: Monomethyl Fumarate (DRUG).
Who is sponsoring clinical trial NCT05978531?
This trial is sponsored by Banner Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI